ECM1通过调节凋亡性细胞死亡和诱导上皮-间质转化来调控结直肠癌对5-氟尿嘧啶治疗的耐药性。

ECM1 regulates the resistance of colorectal cancer to 5-FU treatment by modulating apoptotic cell death and epithelial-mesenchymal transition induction.

作者信息

Long Sirui, Wang Jie, Weng Fanbin, Pei Zhigang, Zhou Shixian, Sun Guiyin, Xiang Debing

机构信息

Department of Oncology, Chongqing University Jiangjin Hospital, Chongqing, China.

Department of Oncology, Jiangjin Central Hospital of Chongqing, Chongqing, China.

出版信息

Front Pharmacol. 2022 Nov 2;13:1005915. doi: 10.3389/fphar.2022.1005915. eCollection 2022.

Abstract

5-Fluorouracil (5-FU) chemoresistance is a persistent impediment to the efficient treatment of many types of cancer, yet the molecular mechanisms underlying such resistance remain incompletely understood. Here we found CRC patients resistant to 5-FU treatment exhibited increased extracellular matrix protein 1 (ECM1) expression compared to CRC patients sensitive to this chemotherapeutic agent, and higher levels of ECM1 expression were correlated significantly with shorter overall survival and disease-free survival. 5-FU resistant HCT15 (HCT15/FU) cells expressed significantly higher levels of ECM1 relative to parental HCT15 cells. Changes in ECM1 expression altered the ability of both parental and HCT15/FU cells to tolerate the medication and processes associated with apoptosis and EMT induction. From a mechanistic perspective, knocking down and overexpressing ECM1 in HCT15/FU and HCT15 cell lines inhibited and activated PI3K/AKT/GSK3β signaling, respectively. Accordingly, 5-FU-induced apoptotic activity and EMT phenotype changes were affected by treatment with PI3K/AKT agonists and inhibitors. Together, these data support a model wherein ECM1 regulates CRC resistance to 5-FU PI3K/AKT/GSK3β pathway-mediated modulation of apoptotic resistance and EMT induction, highlighting ECM1 as a promising target for therapeutic intervention for efforts aimed at overcoming chemoresistance in CRC patients.

摘要

5-氟尿嘧啶(5-FU)耐药性是有效治疗多种癌症的持续障碍,然而这种耐药性背后的分子机制仍未完全明确。我们发现,与对这种化疗药物敏感的结直肠癌(CRC)患者相比,对5-FU治疗耐药的CRC患者细胞外基质蛋白1(ECM1)表达增加,且ECM1的较高表达水平与更短的总生存期和无病生存期显著相关。与亲本HCT15细胞相比,对5-FU耐药的HCT15(HCT15/FU)细胞中ECM1表达水平显著更高。ECM1表达的变化改变了亲本细胞和HCT15/FU细胞耐受药物的能力以及与细胞凋亡和上皮-间质转化(EMT)诱导相关的过程。从机制角度来看,在HCT15/FU和HCT15细胞系中敲低和过表达ECM1分别抑制和激活了PI3K/AKT/GSK3β信号通路。因此,5-FU诱导的凋亡活性和EMT表型变化受到PI3K/AKT激动剂和抑制剂处理的影响。这些数据共同支持了一个模型,即ECM1通过PI3K/AKT/GSK3β途径介导的凋亡抗性和EMT诱导调节来调控CRC对5-FU的耐药性,这突出了ECM1作为克服CRC患者化疗耐药性治疗干预的一个有前景的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/990f/9666402/ea56d4b74fd3/fphar-13-1005915-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索